Oncology and Immunology Research

Aslam S, Li E, Bell E, Lal L, Anderson AJ, Peterson-Brandt J, Lyman G. Risk of chemotherapy-induced febrile neutropenia in intermediate-risk regimens: Clinical and economic outcomes of granulocyte colony-stimulating factor prophylaxis. J Manag Care Spec Pharm, 2023 Feb;29(2):128-138.

Simmons D, Blank SV, ElNaggar AC, Chastek B, Bunner SH, McLaurin K. Health Care Resource Utilization and Costs Associated with Disease Progression in Ovarian Cancer. Adv Ther. 2022 Jun;39(6):2544-61. doi: 10.1007/s12325-022-02086-5. Epub 2022 Apr 1.

Bell EJ, Yu J, Bhatt V, Bunner SH, Lal LS, Galvin J, Weisdorf D. Healthcare Resource Utilization and Costs of Steroid-Associated Complications in Patients With Graft-Versus-Host Disease. Transplantation & Cellular Therapy. 2022 Oct;28(10):707.e1-707.e7 doi:10.1016/j.jtct.2022.04.014

Wallace K, Landsteiner A, Bunner S, Engel-Nitz N, Luckenbaugh A. Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States. Cancer Causes Control. 2021 Dec;32(12):1365-74.

George S, Bell EJ, Zheng Y, Kim R, White JC, Devgan G, Smith J, Lal LS, Engel-Nitz N, Liu FX. The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors. Oncologist. 2021 Jul;26(7):e1205-e1215. doi: 10.1002/onco.13812. Epub 2021 May 29.

Yu J, Lal LS, Anderson A, DuCharme M, Parasuraman S, Weisdorf D. Healthcare resource utilization and costs among patients with steroid-resistant chronic graft-versus-host disease in the United States: a retrospective claims database analysis.  Curr Med Res Opin. 2021 May;37(5):755-759. doi: 10.1080/03007995.2021.1893676. Epub 2021 Mar 10.

DaCosta Byfield S, Wei H, DuCharme M, Lancaster JM. Economic impact of multigene panel testing for hereditary breast and ovarian cancer. J Comp Eff Res. 2021 Feb;10(3):207-217. doi: 10.2217/cer-2020-0192. Epub 2021 Jan 25.

Engel-Nitz NM, Johnson MP, Bunner SH, Ryan KJ. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.  J Manag Care Spec Pharm. 2020 Jun;26(6):729-40.

Clancy Z, Bell EJ, Chastek B, Bunner S, Copher R, Arekapudi S. Treatment patterns and health care costs in patients with follicular lymphoma (FL) or marginal zone lymphoma (MZL). Value in Health. 2020;23 (Suppl. 1):S43.

George S, Bell EJ, Engel-Nitz N, White JC, Lal LS, Liu FX, Kim R, Krulewicz S, Kasturi V, Zheng Y. Immune-related adverse events (irAEs) among urothelial carcinoma (UC) patients treated with PD-1 VS PD-L1 inhibitors: A real-world observational study.  J Clin Oncol. 2020; 38 (Suppl):e17017.

Moses KA, Wallace K, Landsteiner A, Bunner S, Engel-Nitz N, Lal LS, Golsorkhi AA. Real-world evidence of treatment patterns and pharmacy costs among patients with metastatic castration-resistant prostate cancer (mCRPC) in a managed care population in the United States.  J Clin Oncol. 38(15)_suppl. Published online May 25, 2020.

Wallace K, Landsteiner A, Bunner S, Engel-Nitz N, Luckenbaugh A. Epidemiology and mortality of metastatic castration-resistant prostate cancer (mCRPC) in a managed care population in the United States. J Clin Oncol. 38(15)_suppl. Published online May 25, 2020.

Doleh Y, Lal LS, Blauer-Peterson C, Antico G, Pishvaian M . Treatment patterns and outcomes in pancreatic cancer: retrospective claims analysis. Cancer Med. 2020;9(10):3463-76.

Yu J, Lal L, Anderson A, DuCharme M, Parasuraman S, Weisdorf D. . Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation: Data from a large national health insurer. Support Care Cancer. 2020;28(11):5491–99.

Reyes C, Engel-Nitz N, DaCosta Byfield S, Ravelo A, Ogale S, Bancroft T, Anderson A, Chen M, Matasar M. Cost of disease progression in patients with chronic lymphocytic leukemia, acute myeloid leukemia, and non-Hodgkin's lymphoma. Oncologist. 2019 Sep; 2(9):1219-28.

Reyes C, Engel-Nitz N, DaCosta Byfield S, Ravelo A, Ogale S, Bancroft T, Anderson A, Chen M, Matasar M. Cost of disease progression in patients with metastatic breast, lung, and colorectal cancer. Oncologist. 2019 Sep; 24(9):1209-18.

DaCosta Byfield S, Adejoro O, Copher R, Chatterjee D, Joshi PR, Worden FP. Real-World Treatment Patterns Among Patients Initiating Small Molecule Kinase Inhibitor Therapies for Thyroid Cancer in the United States. Adv Ther. 2019 Feb; 36:896-915.

Burton T, LaPuerta P. Economic analysis of inadequate symptom control in carcinoid syndrome in the United States.  Future Oncol. 2018 Oct;14(23):2361-70.

Schwartzberg LS, Lal L, Balu  S, Campbell K, Brekke L, DeLeon A, Elliott C, Korrer S. Clinical outcomes of treatment with filgrastim vs a filgrastim biosimilar and febrile neutropenia-associated costs among patients with nonmyeloid cancer undergoing chemotherapy.  J Manag Care Spec Pharm. 2018 Oct;24(10):976-84.

Schwartzberg LS, Lal L, Balu  S, Campbell K, Brekke L, Elliott C, Korrer S. Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs. a filgrastim biosimilar. Clinicoecon Outcomes Res. 2018 Sep 3;10:493-500.

Burton TM, Ye X, Parker ED, Bancroft T, Healy J. Burden of illness associated with tenosynovial giant cell tumors. Clin Ther. 2018;40(4):593-602.

Mao J, McPheeters JT, Finelli L. Healthcare utilization and costs among patients with herpes zoster and solid tumor malignancy on chemotherapy: a retrospective cohort study. Medicine (Baltimore). 2017 Dec; 96(48):e8746.

Villalobos VM, Byfield SD, Ghate SR, Adejoro O. A retrospective cohort study of treatment patterns among patients with metastatic soft tissue sarcoma in the US. Clin Sarcoma Res. 2017 Nov 9;7:18.

Mudad R, Patel M, Margunato-Debay S, Garofalo D, Lal LS. Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs. gemcitabine plus carboplatin in first-line treatment of advanced squamous non-small cell lung cancer in a US community oncology setting. Lung Cancer (Auckl). 2017 Oct 19;8:179-90.

Rosen VM, Guerra I, McCormack M, Nogueira A, Sasse A, Munk VC, Shang A. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.  Int J Gynecol Cancer. 2017 Jul;27(6):1237-46.

Gildea TR, DaCosta Byfield S, Hogarth DK, Wilson DS, Quinn CC . A retrospective analysis of delays in the diagnosis of lung cancer and associated costs. Clinicoecon Outcomes Res. 2017 May 12;9:261-69.

Fust K, Li X, Maschio M, Villa G, Parthan A, Barron R, Weinstein MC, Somers L, Hoefkens C, Lyman GH. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma. Pharmacoeconomics. 2017 Apr;35(4):425-38.

Fust K, Parthan A, Maschio M, Gu Q, Li X, Lyman GH, Tzivelekis S, Villa G, Weinstein MC. Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: Review of cost-effectiveness models.  Expert Rev Pharmacoecon Outcomes Res. 2017 Feb;17(1):39-52.

Burton T, DaCosta Byfield S, Smith GL, Zanotti G, Bell TJ, Perkins JJ, Horblyuk R, Teitelbaum A. Clinical and economic outcomes by first-line treatment among women with HR+/HER2- metastatic breast cancer in a large US health plan database.  Curr Med Res Opin. 2016 Aug;32(8):14170-23.

DaCosta Byfield S, Buck PO, Blauer-Peterson C, Poston SA. ReCAP: Treatment patterns and cost of care associated with initial therapy among patients diagnosed with operable early-stage human epidermal growth factor receptor 2-overexpressed breast cancer in the United States: A real-world retrospective study. J Oncol Pract. 2016 Feb;12(2):159-67.

Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M, Mueller U, Tang B. Cost-effectiveness analysis of treating acute promyelocytic leukemia patients with arsenic trioxice and retinoic acid in the United States. Clin Lymphoma Myeloma Leuk. 2015 Dec;15(12)771-77.

Engel-Nitz NM, Hao Y, Becker LK, Gerdes R. Costs and mortality of recurrent versus de novo hormone receptor-positive/human epidermal receptor 2-negative metastatic breast cancer.  J Comp Eff Res. 2015 Aug;4(4):303-14.

Kruse M, Wildner R, Barnes G, Martin M, Mueller U, Lo-Coco F, Pathak A. Budgetary impact of treating acute promyelocytic leukemia patients with first-line arsenic trioxide and retinoic acid from an Italian payer perspective.  PLoS One. 2015 Aug 12;10(8):e0134587.

Whyte JL, Engel-Nitz NE, Teitelbaum A, Gomez Rey G, Kallich JD. An evaluation of algorithms for identifying metastatic breast, lung, or colorectal cancer in administrative claims data. Med Care. 2015 Jul;53(7):e49-57.

DaCosta Byfield S, McPheeters JT, Burton TM, Nagar SP, Hackshaw MD. Persistence and compliance among US patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysis.  J Manag Care Spec Pharm. 2015 June;12(6):515-22.

Henk HJ, Li X, Becker LK, Xu H, Gong Q, Deeter RG, Barron RL. Comparative effectiveness of colony-stimulating factors in febrile neutropenia prophylaxis: How results are affected by research design.  J Comp Eff Res. 2015 Jan;4(1):37-50.

Henk HJ, Woloj M, Shapiro M, Whiteley J. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States. Clin Ther. 2015 Jan;37(1):124-33.

Engel-Nitz NM, Yu EB, Becker LK, Small A. Service setting impact on costs for bevacizumab-treated oncology patients.  Am J Manag Care. 2014 Nov;20(11):e515-22.

Fust K, Li X, Maschio M, Barron R, Weinstein MC, Parthan A, Walli-Attaei M, Chandler DB, Lyman GH . Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.  Gynecol Oncol. 2014 Jun;133(3):446-53.

Johnson P, Bancroft T, Barron R, Legg J, Li X, Watson H, Naeim A, Watkins A, Marshall D. Discrete choice experiment to estimate breast cancer patients’ preferences and willingness-to-pay for prophylactic granulocyte colony-stimulating factors.  Value Health. 2014 June;17(4):380-89.

Drummond M, de Pouvourville G, Jones E, Haig J, Saba G, Cawston H. A comparative analysis of two contrasting European approaches for rewarding the value added by drugs for cancer: England versus France. Pharmacoeconomics. 2014 May;32(5):509-20.

Parthan A, Santos E, Becker L, Small A, Lalla D, Brammer M, Teitelbaum A. Health care utilization and costs by site of service for non-metastatic breast cancer patients treated with trastuzumab.  J Manag Care Pharm. 2014 May;20(5):485-93.

Smith BD, Mahmoud D, Dacosta-Byfield S, Rosen VM. Health care utilization and risk of infection and bleeding among MDS patients during periods of transfusion dependence or independence, with or without active therapy.  Leuk Lymphoma. 2014 May;55(5):1119-25.

Smith BD, Beach CL, Mahmoud D, Weber L, Henk HJ. Survival among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis.  Exp Hematol Oncol. 2014 Mar 25;3(1):10.

DaCosta Byfield S, Small A, Becker LK, Reyes CM. Differences in treatment patterns and health care costs among  Non-Hodgkin’s lymphoma and chronic lymphocytic leukemia patients receiving rituximab in the hospital outpatient setting versus the office/clinic setting.  J Cancer Ther. 2014 Feb;5(2):208-16.

Hill G, Barron R, Fust K, Skornicki ME, Taylor DC, Weinstein MC, Lyman GH. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses. J Med Econ. 2014 Jan;17(1):32-42.

DaCosta Byfield S, Chen D, Mi Kim Y, Reyes C. Age distribution of patients with advanced non-melanoma skin cancer in the United States.  Arch Dermatol Res. 2013 Nov;305(9):845-50.

DaCosta Byfield S, Yu E, Morlock R, Evans D, Teitelbaum A. Corroboration of claims algorithm for second-line costs of metastatic colorectal cancer treatment with targeted agents. J Med Econ. 2013 Aug;16(8):1071-81.

Ray S, DaCosta Byfield S, Ganguli A, Bonthapally V, Teitelbaum A. Comparative analysis of survival, treatment, cost and resource use among patients newly diagnosed with brain metastasis by initial primary cancer. J Neurooncol. 2013 Aug;114(1):117-25.

Henk HJ, Chen C, Benedict A, Sullivan J, Teitelbaum A. Retrospective claims analysis of best supportive care costs and survival in a US metastatic renal cell population.  Clinicoecon Outcomes Res. 2013 Jul;5:347-54.

Henk HJ, Ray S. Treatment patterns and healthcare costs among patients with advanced non-small-cell lung cancer.  Lung Cancer Manage. 2013 May;2(3):1-9.

Reyes C, DaCosta Byfield S, Linke R, Satram-Hoang S, Teitelbaum AH. The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs.  Melanoma Res. 2013 Apr;23(2):159-66.

Chastek B, Kulakodlu M, Valluri S, Seal B. Impact of metastatic colorectal cancer stage and number of treatment courses on patient health care costs and utilization.  Postgrad Med. 2013 Mar;125(2):73-82.

Kruse M, Parthan A, Coombs J, Sasane M, Taylor D. Comparison of different adjuvant therapies for 9 resectable cancer types.  Postgrad Med. 2013 Mar;125(2):83-91.

Henk HJ, Kaye J, Rothman K, Becker L, Legg J, Li X, Deeter R. Variation by age in neutropenic complications among patients with cancer receiving chemotherapy.  Community Oncol. 2013 Jan;10(1):16-26.

Naeim A, Henk HJ, Becker L, Chia V, Badre S, Li X, Deeter R. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: A retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF).  BMC Cancer. 2013 Jan;13:11.

Teitelbaum A, Ba-Mancini A, Haung H, Henk HJ. Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: Findings using real-world claims data.  Oncologist. 2013 Jan;18(1):37-45.

Taylor DC, Fust K, Skornicki M, Hill G, Barron R, Weinstein MC. Economic model of granulocyte colony-stimulating factors for patients receiving chemotherapy.  Am J Pharm Benefits. 2012 Dec;4(6):284-92.

Chastek B, Harley C, Kallich J, Newcomer L, Paoli C, Teitelbaum A. Health care costs for patients with cancer at the end of life.  J Oncol Pract. 2012 Nov;8(6):75s-80s.

Engel-Nitz NM, Satram-Hoang S, Cao F, Reyes CM. Lung Cancer: Copayments and behavior following erlotinib formulary tier change.  Am J Pharm Benefits. 2012 Nov; 4(Special Issue):SP6-SP16.

Furst DE, Amato AA, Iorga SR, Bancroft T, Fernandes AW. Medical costs and health care resource use in patients with inflammatory myopathies in an insured population.  Muscle & Nerve. 2012 Oct;46(4):496-505.

Kohli M, Lawrence D, Haig J, Anonychuk A, Demarteau N. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPA)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.  BMC Public Health. 2012 Oct;12:872.

Kruzikas D, Smith JS, Harley C, Buzinec P. Costs associated with management of cervical human papillomavirus-related conditions.  Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1469-78.

Parthan A, Pruttivarasin N, Davies D, Taylor DC, Pawar V, Bijlani A, Lich KH, Chen RC. Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer.  Front Oncol. 2012 Aug;2:81.

Henk HJ, Teitelbaum A, Kaura S. Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid.  Curr Med Res Opin. 2012 Jul;28(7):1119-27.

Baser O, Wei W, Xie L, Henk H, Teitelbaum A. Burden of early stage triple-negative breast cancer in a US managed care plan.  Health Outcomes Research in Medicine. 2012 May;3(2):e57-e65.

Henk HJ, Teitelbaum A, Perez JR, Kaura S. Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma.  Am J Hematol. 2012 May;87(5):490-95.

Baser O, Wei W, Henk HJ, Teitelbaum A, Xie L. Patient survival and health care utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry.  Curr Med Res Opin. 2012 Mar;28(3):419-28.

Lal LS, DaCosta Byfield S, Chang E, Franzini L, Miller LA, Arbuckle R, Reasonda L, Feng C, Adamus A, Swint JM. Cost-effectiveness analysis of a randomized study comparing radiosurgery with radiosurgery plus whole brain radiation therapy in patients with brain metastases.  Am J Clin Oncol. 2012 Feb;35(1):45-50.

Baser O, Wei W, Xie L, Henk HJ, Teitelbaum A. Retrospective study of patients with metastatic triple-negative breast cancer: Survival, health care utilization, and cost.  Community Oncology. 2012 Jan;9(1):8-14.

Engel-Nitz NM, Alemayhu B, Parry D, Nathan F. Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologist versus urologists in a US managed care population.  Cancer Manag Res. 2011 Jul;3:233-45.

Felder TM, Lal LS, Bennett CL, Hung F, Franzini L. Cancer patients’ use of pharmaceutical patient assistance programs in the outpatient pharmacy of a large tertiary cancer center.  Community Oncol. 2011 Jun 1;8(6):279-86.

Haiderali A, Menditto L, Good M, Teitelbaum A, Wegner J. Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population.  Support Care Cancer. 2011 June;19(6):843-51.

Levy DE, Byfield SD, Comstock CB, Garber JE, Syngal S, Crown WH, Shields AE. Underutilization of BRCA1/2 testing to guide breast cancer treatment: Black and Hispanic women particularly at risk.  Genet Med. 2011 Apr;13(4):349-55.

Jonasch E, Lal LS, Atkinson BJ, Byfield SD, Miller LA, Pagliaro LC, Feng C, Tannir NM. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.  BJU Int. 2011 Mar;107(5):741-47.

Lash S, Teitelbaum A, Henk HJ, Reyes CM, Benn L. Costs associated with second-line therapies for lung cancer.  Am J Pharm Benefits. 2011 Feb;3(1):21-29.

Halpern R, Barghout V, Zarotsky V, Williams D. Adherence with imatinib and health care utilization and costs for patients with CML and GIST.   J Clin Outcomes Manage. 2009 May;16(5):215-23.

Schabert VF, Ye X, Insinga RP, Singhal PK, Riedel AA. Five-year routine cervical cancer screening rates and intervals in a US health plan.  Curr Med Res Opin. 2008 Sep;24(9):2429-35.

Kohli M, Ferko N, Martin A, Franco EL, Jenkins D, Gallivan S, Sherlaw-Johnson C, Drummond M. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK.  Br J Cancer. 2007 Jan;96(1):143-50.

Gosselin A, Pashos CL, Harley C, Mark TL, McKenzie RS. Drug administration frequency and provider office visit patterns for oncology patients during treatment with erythropoietic agents: an analysis of four observational studies.  Clin Ther. 2006 Oct;28(10):1701-08.

Cartier S, Zhang B, Rosen VM, Zarotsky V, Bartlett JB, Mukhopadhyay P, Wagner S, Davis C. Relationship between treatment effects on progression-free survival and overall survival in multiple myeloma: a systemic review and meta-analysis of published clinical trial data.  Oncol Res Treat. 2015;38(3):88-94.

Brenneman SK, Belland A, Hulbert E, Leite J, Hall J, Nerenberg M. Can an Integrated Pathology Process and Decision Support Tool Improve Diagnosis and Treatment of Hematologic Malignancies? J Clin Oncol. 2014;32(15):e17622

DaCosta Byfield S, Nash Smyth E, Mytelka D, Bowman L, Teitelbaum A. Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population.  J Med Econ. 2013;16(12):1379-86.

Henk HJ, Becker L, Tan H, Yu J, Kavati A, Naeim A, Deeter R, Barron R. Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses. J Med Econ. 2013;16(1):160-68.

Sanon M, Taylor D, Parthan A, Coombs J, Paolantonio M, Sasane M. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States. J Med Econ. 2013;16(1):150-59.

Henk HJ, Kaura S. Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers.  J Med Econ. 2012;15(1):185-94.

Henk HJ, Kaura S. Retrospective database analysis of the effect of zoledronic acid on skeletal related events and mortality in women with breast cancer and bone metastasis in a managed care plan.  J Med Econ. 2012;15(1):175-84.

Henk HJ, Kaura S, Teitelbaum A. Retrospective database analysis of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases.  J Med Econ. 2012;15(1):195-204.

Tschida SJ, Aslam S, Lal LS, Khan T, Shrank W, Bhattarai G, Montague-Clouse JC, Sahli BD. Retrospective evaluation of an oral oncology specialty pharmacy program.  Am J Pharm Benefits. 2012;4(4):165-74.

Amonkar MM, Chastek B, Samant N, Teitelbaum A. Economic burden of resected squamous cell carcinoma of the head and neck in a US managed-care population.  J Med Econ. 2011;14(4):421-32.

Lau EC, Mowat FS, Kelsh MA, Legg JC, Engel-Nitz NM, Watson HN, Collins HL, Nordyke RJ, Whyte JL. Use of electronic medical records (EMR) for oncology outcomes research: assessing the comparability of EMR information to patient registry and health claims data. Clin Epidemiol. 2011;3:259-72.

Nelson MA, Shetty S, Kulakodlu M, Harley C, Seal B. A comparison of mortality and costs associated with FOLFOX versus FOLFIRI in stage IV colorectal cancer.  J Med Econ. 2011;14(2):179-86.

Alemayehu B, Buysman E, Parry D, Becker L, Nathan F. Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population.  J Med Econ. 2010;13(2):351-61.

Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, Hatfield A, Cortes J. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.  Pharmacoeconomics. 2007;25(6):481-96.

Lal LS, Said Q, Andrade K, Cuker A. Second-line treatment patterns and outcomes for immune thrombocytopenia: a retrospective study of electronic health records. Res Pract Thromb Haemost. 2020 Sep 11;4(7):1131-1140. doi: 10.1002/rth2.12423

Lewiecki EM, Chastek B, Sundquist K, Williams SA, Weiss RJ, Wang Y, Fitzpatrick LA, Curtis JR. Osteoporotic Fracture Trends in a Population of US Managed Care Enrollees from 2007 to 2017.  Osteoporos Int. 2020 Jul;31(7):1299-1304.

Wei W, Gandhi K, Blauer-Peterson C, Johnson J. Impact of Pain Severity and Opioid Use on Health Care Resource Utilization and Costs among Patients with Knee & Hip Osteoarthritis. J Manag Care Spec Pharm. 2019;25(9):957-65.

Buysman EK, Halpern R, Polly DW. Sacroiliac joint fusion health care cost comparison prior to and following surgery: An administrative claims analysis. Clinicoecon Outcomes Res. 2018. Oct 17;10:643-51.

Mao J, Heithoff KA, Koep E, Murphy T, Hammerby E. Cost of subcutaneous immunotherapy in a large insured population in the United States.  Curr Med Res Opin. 2018 Sep;12:1-8.

Walsh JA, Adejoro O, Chastek B, Palmer JB, Hur P. Treatment patterns among patients with psoriatic arthritis treated with a biologic in the United States: Descriptive analyses from an administrative claims database.  J Manag Care Spec Pharm. 2018 Jul;24(7):623-31.

Walsh JA, Adejoro O, Chastek B, Park Y. Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database.  J Comp Eff Res. 2018 Apr;7(4):369-80.

Allen-Ramey FC, Mao J, Blauer-Peterson C, Rock M, Nathan R, Halpern R. Healthcare costs for allergy rhinitis in patients on allergy immunotherapy: A retrospective observational study. Curr Med Res Opin. 2017 Nov;33(11):2039-47.

Armstrong AW, Zhao Y, Herrera V, Li Y, Bancroft T, Hull M, Altan A. Rethinking costs of psoriasis: 10% of patients account for nearly 40% of health care expenditures among enrollees with psoriasis in a US health plan. J Dermatolog Treat. 2017 Nov;28(7):613-22.

Chastek B, Chen CI, Proudfoot C, Shinde S, Kuznik A, Wei W. Treatment persistence and healthcare costs among patients with rheumatoid arthritis changing biologics in the USA.  Adv Ther. 2017 Nov; 34(11):2422–35.

Thorne C, Boire G, Chow A, Garces K, Liu F, Poulin-Costello M, Walker V, Haraoui B. Dose escalation and co-therapy intensification between etanercept, adalimumab, and infliximab: The CADURA Study.  Open Rheumatol. 2017 Oct 24;11:123-35.

Johnson MP, Johnson JC, Engel-Nitz NM, Said Q, Prestifilippo J, Gipson TT, Wheless J. Management of a rare disease population: A model for identifying a patient population with tuberous sclerosis complex.  Manag Care. 2017 Aug;26(8):34-41.

Armstrong AW, Zhao Y, Herrera V, Li Y, Bancroft T, Hull ML, Altan A. Drivers of health care costs among the costliest patients with psoriasis over three years in a US health plan. J Drugs Dermatol. 2017 July; 16(7):651-58.

O'Hanlon CE, Parthan A, Kruse M, Cartier S, Stollenwerk B, Jiang Y, Caloyeras JP, Crittenden DB, Barron R . A model for assessing the clinical and economic benefits of bone-forming agents for reducing fractures in postmenopausal women at high, near-term risk of osteoporotic fracture. Clin Ther. 2017 Jul;39(7):1276-90.

Chastek B, Becker LK, Chen CI, Mahajan P, Curtis JR. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.  J Med Econ. 2017 May;20(5):464-73.

Lofland JH, Johnson PT, Ingham MP, Rosemas SC, White JC, Ellis L. Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs.  Patient Prefer Adherence. 2017 May 18;11:947-58.

Zhang M, Carter C, Olson WH, Johnson MP, Brenneman SK, Lee S, Farahi K. Patient preference for dosing frequency based on prior biologic experience. J Drugs Dermatol. 2017 Mar;16(3):220-26.

Chastek B, White J, Van Voorhis D, Tang D, Stolshek BS. A retrospective cohort study comparing utilization and costs of biologic therapies and JAK inhibitor therapy across four common inflammatory indications in adult US managed care patients.  Adv Ther. 2016 Apr;33(4):626-42.

Altan AA, Shiozawa A, Bancroft T, Singh JA. A real-world study of switching from allopurinol to febuxostat in a health plan database.  J Clin Rheumatol. 2015 Dec;21(8):411-18.

Engel-Nitz NM, Ogale S, Kulakodlu M. Use of anti-tumor necrosis factor therapy: a retrospective study of monotherapy and adherence to combination therapy with non-biologic disease-modifying anti-rheumatic drugs.  Rheumatol Ther. 2015 Dec;2(2):127-39.

Silverman S, Agodoa I, Kruse M, Parthan A, Orwoll E. Denosumab for elderly men with osteoporosis: a cost-effectiveness analysis from the US payer perspective. J Osteoporos. 2015 Dec;2015:627631.

Papaioannou A, Khan A, Belanger A, Bensen W, Kendler D, Theoret F, Amin M, Brekke L, Erdmann M, Walker V, Adachi JD. Persistence with denosumab therapy among osteoporotic women in the Canadian patient-support program.  Curr Med Res Opin. 2015 Jun;31(7):1391-401.

Yu J, Brenneman SK, Sazonov V, Modi A. Reasons for not initiating osteoporosis therapy among a managed care population. Patient Prefer Adherence. 2015 Jun 19;9:821-30.

Zhang M, Brenneman SK, Carter C, Essoi B, Farahi K, Johnson MP, Lee S, Olson WH. Patient-reported treatment satisfaction and choice of dosing frequency with biologic treatment of moderate to severe plaque psoriasis. Patient Prefer Adherence. 2015 Jun;9:777–84.

Curtis JR, Chastek B, Becker L, Quach C, Harrison DJ, Yun H, Joseph GJ, Collier DH. Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population.  J Managed Care Spec Pharm. 2015 Apr;21(4):318-29.

Parthan A, Kruse M, Agodoa I, Silverman S, Orwoll E. Denosumab: A cost-effective alternative for older men with osteoporosis from a Swedish payer perspective. Bone. 2014 Feb;59:105-13.

Edson-Heredia E, Sterling KL, Alatorre CI, Cuyun Carter G, Paczkowski R, Zarotsky V, Maeda-Chubachi T. Heterogeneity of response to biologic treatment: perspective for psoriasis.  J Invest Dermatol. 2014 Jan;134(1):18-23.

Thayer S, Stolshek BS, Gomez Rey G, Seare JG. Impact of osteoporosis on high-cost chronic diseases.  Value Health. 2014 Jan-Feb;17(1):43-50.

Chastek B, Segal S, Bonafede RP, Watson C, Becker L, Chaudhari S, Harrison DJ, Gandra SR. Comparative effectiveness of TNF blockers in rheumatoid arthritis patients.  Am J Pharm Benefits. 2013;5(Special Issue):SP14-SP22.

Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.  Appl Health Econ Health Policy. 2013 Oct;11(5):485-97.

Brenneman SK, Yurgin N, Fan Y. Cost and management of males with closed fractures. Osteoporosis Int. 2013 Mar;24(3):825-33.

Curtis JR, Chastek B, Becker L, Harrison DJ, Collier D, Yun H, Joseph G. Further evaluation of a claims based algorithm to determine the effectiveness of biologics for rheumatoid arthritis using commercial claims data. Arthritis Res Ther. 2013 Mar;15(2):404.

Chastek B, Fox KM, Watson C, Kricorian G, Gandra SR. Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population. J Dermatolog Treat. 2013 Feb;24(1):25-33.

Furst DE, Clarke AE, Fernandes AW, Bancroft T, Greth W, Iorga SR. Incidence and prevalence of adult systemic lupus erythematosus in a large US managed-care population. Lupus. 2013 Jan;22(1):99-105.

Chastek B, Fox KM, Watson C, Gandra SR. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan. Adv Ther. 2012 Aug;29(8):691-97.

Bombardier C, Barbieri M, Parthan A, Zack DJ, Walker V, Macarios D, Smolen JS. The relationship between joint damage and functional disability in rheumatoid arthritis: A systematic review.  Ann Rheum Dis. 2012 Jun;71(6):836-44.

Ogale S, Hitraya E, Henk HJ. Patterns of biologic agent utilization among patients with rheumatoid arthritis: A retrospective cohort study.  BMC Musculoskeletal Disord. 2011 Sep;12:204.

Goetz I, Carter GC, Lucero M, Zarotsky V, Alatorre CI, Cantrell RA, Paczkowski R, Sterling KL. Review of treatment response in rheumatoid arthritis: assessment of heterogeneity.  Curr Med Res Opin. 2011 Apr;27(4):697-711.

Halpern R, Becker L, Usman Iqbal S, Kazis L, Macarios D, Badamgarav E. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: A retrospective claims analysis of female health plan enrollees with osteoporosis.  J Manag Care Pharm. 2011 Jan;17(1):25-39.

Bellamy N, Bell MJ, Goldsmith CH, Lee S, Maschio M, Raynauld JP, Torrance GW, Tugwell P. BLISS index using WOMAC index detects between-group differences at low-intensity symptom states in osteoarthritis. J Clin Epidemiol. 2010 May;63(5):566-74.

Thayer S, Watson C, Song R, Globe DR, Harrison DJ. Etanercept treatment patterns in managed-care patients with psoriasis or psoriatic arthritis. J Med Econ. 2010 May;13(2):228-35.

Copher R, Buzinec P, Zarotsky V, Kazis L, Iqbal SU, Macarios D. Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims. Curr Med Res Opin. 2010 Apr;26(4):777-85.

Yazici Y, McMorris BJ, Darkow T, Rosenblatt LC. Patient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritis.  Clin Exp Rheumatol. 2009 Nov-Dec;27(6):907-13.

Adachi JD, Kennedy CC, Papaioannou A, Ioannidis G, Leslie WD, Walker V. Treating osteoporosis in Canada: What clinical efficacy data should be considered by policy decision makers?  Osteoporos Int. 2009 Oct;20(10):1785-93.

Borah BJ, Huang X, Zarotsky V, Globe D. Trends in rheumatoid arthritis patients’ adherence to subcutaneous anti-TNF therapies and costs. Curr Med Res Opin. 2009 Jun;25(6):1365-77.

Gold DT, Martin BC, Frytak JR, Amonkar MM, Cosman F. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis.  Curr Med Res Opin. 2007 Mar;23(3):585-95.

Bellamy N, Bell MJ, Goldsmith CH, Pericak D, Walker V, Raynauld JP, Torrance GW, Tugwell P, Polisson R  . Evaluation of WOMAC 20, 50, 70 response criteria in patients treated with hylan G-F 20 for knee osteoarthritis.  Ann Rheum Dis. 2005 Jun;64(6):881-85.

Bellamy N, Bell MJ, Goldsmith CH, Pericak D, Walker V, Raynauld JP, Torrance GW, Tugwell P, Polisson R . The effectiveness of hylan G-F 20 in patients with knee osteoarthritis: an application of two sets of response criteria developed by the OARSI and one set developed by OMERACT-OARSI.  Osteoarthritis Cartilage. 2005 Feb;13(2):104-10.

Harley C, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate.  Am J Manag Care. 2003 Oct;9(6 Suppl):S136-43.

Torrance GW, Raynauld JP, Walker V, Goldsmith CH, Bellamy N, Band PA, Schultz M, Tugwell P. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results.  Osteoarthritis Cartilage. 2002 Jul;10(7):518-27.

Garris C, Jhingran P, Bass D, Engel-Nitz NM, Riedel A, Dennis G. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan.  J Med Econ. 2013;16(5):667-77.

Chau D, Becker D, Coombs M, Ioannidis G, Adachi J, Goeree R . Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada. J Med Econ. 2012;15(S1):3-14.